Shingrix Shingles Vaccine

Shingrix is the recombinant zoster vaccine used to help protect adults against shingles (herpes zoster) and its complications, most notably postherpetic neuralgia. For pharmacies, clinics, and immunization programs, keeping it in stock means being ready for the patients most at risk—typically adults aged 50 and older, and immunocompromised adults 19 and older whose providers recommend it.

The vaccine is administered as a two-dose series, with the second dose given two to six months after the first. Because Shingrix is a non-live, adjuvanted vaccine, it requires refrigerated storage between 2°C and 8°C and must not be frozen. Each carton is supplied with separate lyophilized antigen and adjuvant suspension components that are reconstituted immediately before administration, so proper cold-chain handling and inventory rotation are essential to preserving potency.